article Open AccessTop 1% cited

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

The Journal of Urology · 2017 · Vol. 198(3) · pp. 552–559

Sam S. Chang✉(Society of Urologic Oncology)Bernard H. Bochner(American Society for Radiation Oncology)Roger Chou(American Society for Radiation Oncology)Robert Dreicer(American Urological Association)Ashish M. Kamat(Society of Urologic Oncology)Seth P. Lerner(American Society for Radiation Oncology)Yair Lotan(Society of Urologic Oncology)Joshua J. Meeks(American Society of Clinical Oncology)Jeff M. Michalski(American Society for Radiation Oncology)Todd M. Morgan(American Society for Radiation Oncology)Diane Zipursky Quale(American Society of Clinical Oncology)Jonathan E. Rosenberg(American Society of Clinical Oncology)Anthony L. Zietman(American Society of Clinical Oncology)Jeffrey M. Holzbeierlein(American Urological Association)

View via DOI Publisher page

Abstract

The intensity and scope of care for muscle-invasive bladder cancer should focus on the patient, disease and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.

Bladder and Urothelial Cancer Treatments Urinary and Genital Oncology Studies Urological Disorders and TreatmentsMedicineGuidelineBladder cancerUrologyGynecologyOncologyInternal medicineCancerPathology

MeSH terms

AlgorithmsAntineoplastic AgentsUrinary Bladder NeoplasmsCombined Modality TherapyHumansNeoplasm InvasivenessNeoplasm StagingCystectomyWatchful Waiting

Citations

926

FWCI

75.65

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Study on evaluation of bladder neoplasms using MDCT virtual cystoscopy versus conventional cystoscopy